HTS – Electrophysiology Services

Ion channels continue to be important therapeutic targets for a range of indications including arrhythmia, hypertension, local anesthesia, pain, stroke, epilepsy, depression, bipolar disorder, COPD, autoimmune disorders, and diabetes. Ion channels are not only important drug targets, but they are also critically important in evaluating drug safety. Many drugs withdrawn from the market due to cardiac-related adverse effects have been shown to block the human ether-a-go-go (hERG) ion channel, which delays repolarization of the cardiac action potential and can result in a potentially fatal arrhythmia known as Torsades de Pointes (TdP).
 
Automated Patch Clamp (APC) Electrophysiology has had a major impact on drug discovery since its development more than two decades ago, and it will continue to play a significant role in ion-channel drug discovery and safety testing in years to come. The need for rapid, cost-effective, high quality, high-throughput APC screening has become a necessity, as the importance of ion channels for discovery of novel drug therapies for diseases and de-risking adverse cardiovascular effects increases.
 
At Eurofins Discovery, we have an industry leading portfolio of ion channel cell lines, technology platforms and a dedicated team of experienced electrophysiologists to help you determine the right assay format (binding and/or functional) all the way through data interpretation. From single-cell manual patch clamp (the gold standard in ion channel work) to high-throughput 384-well automated electrophysiology instruments, we have the capabilities to utilize platforms and strategies that provide the throughput, results, and depth of analysis to meet your drug discovery requirements.

Eurofins Discovery HTS Electrophysiology Services

Functional Target Based Discovery for Ion Channels – HTS cell-based functional assays for more than 60 ion channels to support drug discovery screening efforts. Full project support, both scientific and technical, for ion channel drug discovery utilizing HTS Qube384 automated electrophysiology platform technology along with other supporting platforms.
 
Safety Testing for Cardiac Ion Channels – HTS of hERG and other cardiac ion channel targets, as recommended by CiPA, for early cardiac risk assessment and mitigation. HTS testing available on Qube384 platform in both single concentration and dose response formats.